2025 HFSA CME Symposium - Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure: New Opportunities to Improve Patient Outcomes

This CME Symposium takes place on Sunday, September 28, 2025, from 5:30PM - 6:45PM CT during the 2025 Annual Scientific Meeting of the Heart Failure Society of America at the Hilton Minneapolis in Minneapolis, Minnesota.

HAZLET, N.J. - Aug. 19, 2025 - PRLog -- In this symposium, Chair Dr. Mathew Maurer, and faculty members Dr. Noel Dasgupta, Dr. Omar Abou Ezzeddine, and Dr. Frederick Ruberg, will explain best practices for screening and diagnosing ATTR-CM in patients with concomitant HF, describe the treatment landscape, and, through case presentation, discuss practical considerations in management.

Click here for more information

CHAIR

Mathew Maurer, MD
Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center
Vagelos College of Physicians & Surgeons
New York, New York

FACULTY

Noel Dasgupta, MD
Associate Professor of Clinical Medicine and
Pathology & Laboratory Medicine
Indiana University School of Medicine
Indianapolis, Indiana

Omar Abou Ezzeddine, MD, MS
Associate Professor of Medicine
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Frederick Ruberg, MD
Chief of Cardiovascular Medicine
Boston Medical Center
Thomas J. Ryan Professor of Cardiovascular Medicine
Boston University Chobanian & Avedisian School of Medicine
Boston, Massachusetts

Educational Objectives

• Identify red flags which raise suspicion for ATTR-CM in HF patients
• Discuss the diagnostic tests to quickly and accurately diagnose ATTR-CM
• Explain the evidence and effectiveness of traditional HF medications in patients with ATTR-CM
• Summarize the evolving landscape for ATTR-CM therapies
• Recognize how patient monitoring and assessment is constantly changing and improving

Target Audience
This educational activity is intended for clinicians who manage patients with heart failure.

Educational Grant
Voxmedia gratefully acknowledges the independent educational grant provided by Alnylam Pharmaceuticals, Inc.

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live activity for a maximum of 1.25 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Contact
Voxmedia, LLC
***@voxmedia.us

Photos: (Click photo to enlarge)




Source: CMEPlanet

Read Full Story - 2025 HFSA CME Symposium - Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure: New Opportunities to Improve Patient Outcomes | More news from this source

Press release distribution by PRLog